Commentary Statin discontinuation: counterbalancing the benefits with the potential risks

Paraskevas, Kosmas I.; Koupidis, Sotirios A; Gentimi, Fotini; Tzovaras, Alexandros

doi:10.5114/aoms.2011.26622

Cited by 4 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite well-established roles in primary and secondary prevention of CVD, due to their positive effects on the plasma lipid profile, statin use is associated with some side effects and residual risk [ 24 ]. Beyond their potent pharmacologic inhibition of cholesterol biosynthesis, statins appear to have pleiotropic effects, including antiarrhythmic, antiinflammatory, antioxidative, antithrombotic, antimitotic, antibacterial, C reactive protein-lowering, angiogenic, immunomodulatory and vascular protective (stabilization of the atheroma plaque) activity, inhibition of smooth muscle cell proliferation and migration, inhibition of cardiac remodeling, inhibition of matrix metalloproteinase and cyclooxygenase-2, inhibition of telomere shortening, and improvement of microvascular function (amelioration of endothelial function) and of autonomic nervous system function [ 25 – 27 ].…”

Section: Lipid Update 2013mentioning

confidence: 99%

Lipid, blood pressure and kidney update 2013

et al. 2014

View full text Add to dashboard Cite

The year 2013 proved to be very exciting as far as landmark trials and new guidelines in the field of lipid disorders, blood pressure and kidney diseases. Among these are the International Atherosclerosis Society Global Recommendations for the Management of Dyslipidemia, European Society of Cardiology (ESC)/European Society of Hypertension Guidelines for the Management of Arterial Hypertension, American Diabetes Association Clinical Practice Recommendations, the Kidney Disease: Improving Global Outcomes Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease (CKD) Patients, the American College of Cardiology/American Heart Association Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults, the Joint National Committee Expert Panel (JNC 8) Evidence-Based Guideline for the Management of High Blood Pressure in Adults, the American Society of Hypertension/International Society of Hypertension Clinical Practice Guidelines for the Management of Hypertension in the Community, the American College of Physicians Clinical Practice Guideline on Screening, Monitoring, and Treatment of Stage 1–3 CKD and many important trials presented among others during the ESC Annual Congress in Amsterdam and the American Society of Nephrology Annual Meeting—Kidney Week in Atlanta, GA. The paper is an attempt to summarize the most important events and reports in the mentioned areas in the passing year.

show abstract

Section: Lipid Update 2013mentioning

confidence: 99%

Lipid, blood pressure and kidney update 2013

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In contrast, there is evidence that statin discontinuation leads to a rebound effect and an overshoot reversal of many beneficial pleiotropic effects. 32 –34…”

mentioning

confidence: 99%

“…In contrast, there is evidence that statin discontinuation leads to a rebound effect and an overshoot reversal of many beneficial pleiotropic effects. [32][33][34] Future studies should evaluate the effects of thrombolysis on the incidence and extent of postprocedural ischemic strokes associated with CAS procedures. The majority of CASassociated strokes occur during the procedure or in the first 30 days postprocedurally.…”

mentioning

confidence: 99%

Thrombolysis May Reduce the Incidence/Extent of Postprocedural Ischemic Strokes Associated With Carotid Artery Stenting

Paraskevas

Veith

2014

Angiology

Self Cite

View full text Add to dashboard Cite

“…In their mini-review/short communication in this issue of the Archives of Medical Science , Dr. Paraskevas et al [ 1 ] draw proper attention to the consequences of statin discontinuation. They focus primarily on the cerebrovascular disease but their conclusion that absolute benefits of discontinuation are small and the absolute risks are high is consistent with a large and robust totality of evidence.…”

mentioning

confidence: 99%